Cargando…

Early antibody responses associated with survival in COVID19 patients

Neutralizing antibodies to the SARS CoV-2 spike proteins have been issued Emergency Use Authorizations and are a likely mechanism of vaccines to prevent COVID-19. However, benefit of treatment with monoclonal antibodies has only been observed in clinical trials in outpatients with mild to moderate C...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Zhao-Hua, Dharmarajan, Sai, Lehtimaki, Mari, Kirshner, Susan L., Kozlowski, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321400/
https://www.ncbi.nlm.nih.gov/pubmed/34280244
http://dx.doi.org/10.1371/journal.ppat.1009766
_version_ 1783730842133069824
author Zhou, Zhao-Hua
Dharmarajan, Sai
Lehtimaki, Mari
Kirshner, Susan L.
Kozlowski, Steven
author_facet Zhou, Zhao-Hua
Dharmarajan, Sai
Lehtimaki, Mari
Kirshner, Susan L.
Kozlowski, Steven
author_sort Zhou, Zhao-Hua
collection PubMed
description Neutralizing antibodies to the SARS CoV-2 spike proteins have been issued Emergency Use Authorizations and are a likely mechanism of vaccines to prevent COVID-19. However, benefit of treatment with monoclonal antibodies has only been observed in clinical trials in outpatients with mild to moderate COVID-19 but not in patients who are hospitalized and/or have advanced disease. To address this observation, we evaluated the timing of anti SARS-CoV-2 antibody production in hospitalized patients with the use of a highly sensitive multiplexed bead-based immunoassay allowing for early detection of antibodies to SARS-CoV-2. We found significantly lower levels of antibodies to the SARS-CoV-2 spike protein in the first week after symptom onset in patients who expired as compared to patients who were discharged. We also developed a model to characterize the relationship between each patient’s individual antibody level trajectory and eventual COVID 19 outcome which can be adapted into a prediction model with more data.
format Online
Article
Text
id pubmed-8321400
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-83214002021-07-31 Early antibody responses associated with survival in COVID19 patients Zhou, Zhao-Hua Dharmarajan, Sai Lehtimaki, Mari Kirshner, Susan L. Kozlowski, Steven PLoS Pathog Research Article Neutralizing antibodies to the SARS CoV-2 spike proteins have been issued Emergency Use Authorizations and are a likely mechanism of vaccines to prevent COVID-19. However, benefit of treatment with monoclonal antibodies has only been observed in clinical trials in outpatients with mild to moderate COVID-19 but not in patients who are hospitalized and/or have advanced disease. To address this observation, we evaluated the timing of anti SARS-CoV-2 antibody production in hospitalized patients with the use of a highly sensitive multiplexed bead-based immunoassay allowing for early detection of antibodies to SARS-CoV-2. We found significantly lower levels of antibodies to the SARS-CoV-2 spike protein in the first week after symptom onset in patients who expired as compared to patients who were discharged. We also developed a model to characterize the relationship between each patient’s individual antibody level trajectory and eventual COVID 19 outcome which can be adapted into a prediction model with more data. Public Library of Science 2021-07-19 /pmc/articles/PMC8321400/ /pubmed/34280244 http://dx.doi.org/10.1371/journal.ppat.1009766 Text en https://creativecommons.org/publicdomain/zero/1.0/This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
spellingShingle Research Article
Zhou, Zhao-Hua
Dharmarajan, Sai
Lehtimaki, Mari
Kirshner, Susan L.
Kozlowski, Steven
Early antibody responses associated with survival in COVID19 patients
title Early antibody responses associated with survival in COVID19 patients
title_full Early antibody responses associated with survival in COVID19 patients
title_fullStr Early antibody responses associated with survival in COVID19 patients
title_full_unstemmed Early antibody responses associated with survival in COVID19 patients
title_short Early antibody responses associated with survival in COVID19 patients
title_sort early antibody responses associated with survival in covid19 patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321400/
https://www.ncbi.nlm.nih.gov/pubmed/34280244
http://dx.doi.org/10.1371/journal.ppat.1009766
work_keys_str_mv AT zhouzhaohua earlyantibodyresponsesassociatedwithsurvivalincovid19patients
AT dharmarajansai earlyantibodyresponsesassociatedwithsurvivalincovid19patients
AT lehtimakimari earlyantibodyresponsesassociatedwithsurvivalincovid19patients
AT kirshnersusanl earlyantibodyresponsesassociatedwithsurvivalincovid19patients
AT kozlowskisteven earlyantibodyresponsesassociatedwithsurvivalincovid19patients